Chloramphenicol, the active antibacterial substance in Chloramphenicol capsules, is reserved for selected serious bacterial infections when other options are unsuitable. It stops susceptible bacteria producing essential proteins, but its potential for serious blood toxicity means treatment requires careful clinical selection and monitoring.
Chloramphenicol is a broad-spectrum antibiotic from the amphenicol class. Oral capsules may be used only in carefully selected bacterial infections, usually when the organism is susceptible and safer alternatives are unsuitable or ineffective. Its use is limited because rare but severe bone-marrow toxicity can occur, including aplastic anaemia.
The medicine does not treat viral illnesses such as influenza, most sore throats, or viral gastroenteritis. It also has no useful effect against fungal infections. A bacterial diagnosis, culture result, or strong clinical reason is needed before treatment is selected.
The product sold on this page is supplied as capsules for oral administration. The capsule should be swallowed with water and should not be opened, crushed, or chewed unless a prescriber or pharmacist has given a specific instruction for that formulation.
The active substance is chloramphenicol. It is an antibacterial antibiotic, not a painkiller, anti-inflammatory medicine, or treatment for an unexplained fever.
The exact regimen for the chosen strength must be confirmed with a healthcare professional before starting. The dose depends on the infection, age, body weight, organ function, susceptibility results, and the selected capsule strength.
Systemic chloramphenicol has specialist uses in infections caused by susceptible bacteria. Historically, it has been used for serious infections such as typhoid fever, meningitis, rickettsial disease, and selected anaerobic infections. Modern practice often favours other antibiotics when they provide comparable antibacterial coverage with a lower toxicity burden.
Symptoms such as fever, headache, diarrhoea, neck stiffness, confusion, or worsening weakness do not identify the causative organism by themselves. Taking Chloramphenicol capsules for an undiagnosed illness can delay the right treatment and expose the patient to avoidable harm.
Antibiotic stewardship means using an antibiotic only when it is likely to help, at the correct dose, for the shortest clinically suitable course. Chloramphenicol should not be shared with another person or saved for a later illness.
Stopping early can leave surviving bacteria behind. Unnecessary use also increases selective pressure that favours resistant organisms.
Chloramphenicol has a place in limited specialist treatment of serious bacterial infections. Its historical role included enteric fever and bacterial meningitis, while current use is more selective because other antibiotics may offer a better safety profile.
Tetracycline-resistant cholera has been described as a specialist infectious-disease context for chloramphenicol. This does not make Chloramphenicol capsules suitable for self-treatment of diarrhoea. Cholera requires rapid fluid and electrolyte management, microbiological and public-health considerations, and expert antibiotic selection.
The WHO Model List of Essential Medicines recognises chloramphenicol within carefully defined antibacterial treatment contexts, while also reflecting the need for responsible selection [2]. A capsule intended for systemic treatment should never be used to treat an eye problem without specific clinical direction.
The regimen for the chosen strength is confirmed with a healthcare professional before starting. There is no single universal dose that is appropriate for every person or every infection.
Use depends on:
Take each capsule at the prescribed interval. Swallow it with water. Avoid changing the schedule because symptoms improve after a few doses.
If a dose is missed, take it when remembered unless the next dose is due soon. Do not double the next dose. A clinician or pharmacist can give the exact missed-dose instruction when the timing is unclear.
Common errors include taking an old course for a new illness, doubling a missed dose, stopping when fever falls, or combining the antibiotic with another prescription without checking for interactions. Another practical problem is failing to mention previous blood disorders or unexplained bruising before treatment begins.
Chloramphenicol should not be used by a person with a previous serious reaction to chloramphenicol or a known history of chloramphenicol-associated aplastic anaemia.
Extra caution is needed with:
Warfarin is a specific interaction concern because chloramphenicol can increase anticoagulant effects in some patients. This may raise the INR and bleeding risk, requiring clinical monitoring and possible adjustment.
Phenytoin and phenobarbital may interact through hepatic enzyme effects. Chloramphenicol can also affect the handling of some oral diabetes medicines and other drugs with a narrow therapeutic range.
Medsafe safety information highlights the need to consider serious haematological reactions when chloramphenicol is prescribed. The European Medicines Agency also treats blood dyscrasias and severe medicine reactions as events requiring rapid clinical evaluation [3].
Chloramphenicol is not for you if a clinician has not diagnosed a susceptible bacterial infection, if a safer suitable option exists, or if the required monitoring cannot be arranged. Tell a clinician before treatment if you have had serious blood problems or a serious reaction to this medicine. Extra care is needed if you have liver problems, are pregnant or breastfeeding, are receiving chemotherapy, or take medicines such as warfarin or seizure treatments.
The most important safety issue is the potential for bone-marrow suppression. This may cause anaemia, low white-cell counts, low platelet counts, or pancytopenia. Rare idiosyncratic aplastic anaemia can occur during treatment or after exposure, and it is not reliably predicted by the dose.
Possible warning symptoms include:
Seek urgent medical assessment for unexplained bleeding, a new severe infection, marked weakness, confusion, collapse, or breathing difficulty.
Nausea, vomiting, diarrhoea, headache, and altered taste can occur with oral antibiotic treatment. A mild symptom may settle, but persistent or severe diarrhoea can indicate antibiotic-associated colitis and needs prompt medical review.
Serious allergic reactions may include facial swelling, wheezing, widespread hives, blistering skin, or difficulty breathing. These symptoms require emergency care rather than another dose.
Longer exposure raises concern about cumulative toxicity, especially when the indication is uncertain or monitoring is absent. Chloramphenicol can also interact with medicines metabolised by liver enzymes and may alter the effects of anticoagulants, anticonvulsants, or some diabetes medicines.
Chloramphenicol enters susceptible bacterial cells and binds to the 50S subunit of the bacterial ribosome. Ribosomes are the structures that assemble proteins. By blocking peptidyl transferase activity, chloramphenicol interrupts bacterial protein synthesis [1].
In plain language, the medicine prevents susceptible bacteria from making the proteins needed for growth, repair, and reproduction.
The mechanism affects bacterial ribosomes more strongly than human cytoplasmic ribosomes, although chloramphenicol can interfere with mitochondrial protein synthesis in human cells. This mitochondrial effect helps explain why serious blood and organ toxicities are biologically possible.
The drug reaches different tissues after oral administration. Its distribution is influenced by inflammation, protein binding, liver metabolism, and the integrity of the blood–brain barrier. These properties once made chloramphenicol valuable for infections involving the central nervous system.
Chloramphenicol is usually described as bacteriostatic, meaning it stops bacterial growth rather than directly killing bacteria. Against some organisms, at certain concentrations, or in particular clinical settings, it may show bactericidal activity.
Laboratory behaviour does not replace susceptibility testing. A bacterium that appears sensitive in vitro may still require a different treatment because of tissue penetration, resistance development, infection severity, or the patient’s medical history.
| Treatment approach | Main clinical distinction | Practical limitation |
|---|---|---|
| Oral Chloramphenicol | Broad antibacterial activity with useful tissue penetration in selected infections | Serious blood toxicity limits routine use |
| Narrow-spectrum antibiotic | Targets a confirmed or strongly suspected susceptible organism | May fail if the diagnosis or susceptibility is wrong |
| Local antibiotic preparation | Delivers medicine to a limited site, such as the skin or eye | Does not treat a deep or systemic infection |
A targeted antibiotic is often preferred when laboratory results identify a safer option. Chloramphenicol may remain appropriate in specialist care when resistance, allergy, tissue penetration, or treatment history narrows the choices.
Chloramphenicol capsules should not be substituted for topical eye preparations. A systemic capsule is not a replacement for an eye drop or ointment regimen, and an ophthalmic product cannot treat a bloodstream or intestinal infection.
In clinical practice, physicians usually reserve systemic chloramphenicol for situations in which the expected antibacterial benefit outweighs its unusual but serious toxicity risk. The decision is stronger when cultures identify a susceptible organism and safer alternatives are unsuitable.
A doctor will usually want to know about previous anaemia, low blood counts, liver disease, pregnancy, breastfeeding, and medicines that affect bleeding or bone marrow. Blood testing may be needed before or during treatment, depending on the course length and the person’s risk factors.
One detail patients often miss is that improvement in fever does not prove the infection has been eradicated. Symptoms can ease before the bacterial burden has been adequately controlled. The prescribed course and follow-up plan still matter.
Medsafe information from 2025 supports age-specific prescribing decisions rather than routine self-use in children. Chloramphenicol can be especially hazardous in newborns and young infants because immature drug handling may lead to accumulation and serious toxicity. Medsafe monitoring advice should be followed when treatment extends beyond a short specialist course. In older children, the dose is calculated from factors such as body weight, infection, and organ function. A paediatrician or other prescriber must confirm the regimen before a child receives Chloramphenicol capsules.
Chloramphenicol acts on the bacterial 50S ribosomal subunit and inhibits protein synthesis, while many alternative antibiotics act on different bacterial targets. Its broad activity can be useful in selected infections, but broad coverage does not make it the preferred option for every diagnosis. WHO guidance from 2023 supports matching antibiotic selection to the organism and infection rather than choosing the broadest medicine automatically. Culture results and local resistance data often favour a narrower option.
Warfarin is a clinically important combination because chloramphenicol may increase anticoagulant activity and bleeding risk. Medsafe interaction information from 2025 supports arranging clinical monitoring when these medicines are used together. The same review should include phenytoin, phenobarbital, diabetes medicines, chemotherapy, vitamins, and herbal products. Do not start a supplement during the course without checking its ingredients and interaction potential.
The course length depends on the infection, culture results, response, and the prescriber’s treatment plan. Long-term or repeated use is not a routine choice because chloramphenicol can cause severe blood toxicity and other adverse effects. The FDA prescribing information, reviewed in 2019, limits use to situations where the expected benefit justifies the risk. A person should not extend, repeat, or taper the course independently.
Some symptoms may begin to improve after effective treatment has been established, but the timing varies with the infection and its severity. The absence of early improvement can indicate resistance, an incorrect diagnosis, a complication, or inadequate drug exposure. EMA safety principles from 2024 support reassessment when a patient worsens or fails to respond as expected. Persistent fever, new pain, confusion, breathing difficulty, or dehydration needs prompt clinical review.
Pregnancy and breastfeeding require an individual benefit–risk assessment before Chloramphenicol is used. Chloramphenicol can cross the placenta and enter breast milk, while newborns have limited capacity to clear the medicine. Medsafe information from 2025 supports discussing pregnancy status, breastfeeding, and the infant’s age before treatment begins. A safer alternative may be selected when it can adequately treat the infection.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I took the capsules for a confirmed bacterial infection. The fever eased after several days, but nausea made the first part of the course difficult. Taking each dose with water and keeping meals simple helped.
The treatment was selected after another antibiotic had not worked. I improved, but I was worried about the blood-test appointment and did not skip it. The main problem was a metallic taste that lasted through the course.
I missed one dose during a night shift and nearly doubled the next one. The pharmacist told me not to do that. My symptoms improved, although the medicine caused loose stools for several days.
The infection settled after the prescribed course, but I felt unusually tired near the end. The clinic arranged blood tests, and I was told to stop while they checked the result. That tiredness should not be ignored.
